630 related articles for article (PubMed ID: 22828645)
41. Immune response and one-year antibody persistence after a fourth dose of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY) at 12 to 15 months of age.
Marshall GS; Marchant CD; Blatter M; Aris E; Boutriau D; Poolman JT; Friedland LR; Miller JM
Pediatr Infect Dis J; 2010 May; 29(5):469-71. PubMed ID: 20072077
[TBL] [Abstract][Full Text] [Related]
42. Five-year Antibody Persistence and Booster Response to a Single Dose of Meningococcal A, C, W and Y Tetanus Toxoid Conjugate Vaccine in Adolescents and Young Adults: An Open, Randomized Trial.
Baxter R; Baine Y; Kolhe D; Baccarini CI; Miller JM; Van der Wielen M
Pediatr Infect Dis J; 2015 Nov; 34(11):1236-43. PubMed ID: 26237742
[TBL] [Abstract][Full Text] [Related]
43. Salivary antibody levels in adolescents in response to a meningococcal serogroup C conjugate booster vaccination nine years after priming: systemically induced local immunity and saliva as potential surveillance tool.
Stoof SP; van der Klis FR; van Rooijen DM; Bogaert D; Trzciński K; Sanders EA; Berbers GA
Vaccine; 2015 Jul; 33(32):3933-9. PubMed ID: 26100925
[TBL] [Abstract][Full Text] [Related]
44. Randomized Trial to Compare the Immunogenicity and Safety of a CRM or TT Conjugated Quadrivalent Meningococcal Vaccine in Teenagers who Received a CRM or TT Conjugated Serogroup C Vaccine at Preschool Age.
Ishola DA; Andrews N; Waight P; Yung CF; Southern J; Bai X; Findlow H; Matheson M; England A; Hallis B; Findlow J; Borrow R; Miller E
Pediatr Infect Dis J; 2015 Aug; 34(8):865-74. PubMed ID: 26075813
[TBL] [Abstract][Full Text] [Related]
45. Immunogenicity and safety of an investigational combined haemophilus influenzae type B-Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine.
Nolan T; Richmond P; Marshall H; McVernon J; Alexander K; Mesaros N; Aris E; Miller J; Poolman J; Boutriau D
Pediatr Infect Dis J; 2011 Mar; 30(3):190-6. PubMed ID: 20948453
[TBL] [Abstract][Full Text] [Related]
46. Immunogenicity and safety of a combination pneumococcal-meningococcal vaccine in infants: a randomized controlled trial.
Buttery JP; Riddell A; McVernon J; Chantler T; Lane L; Bowen-Morris J; Diggle L; Morris R; Harnden A; Lockhart S; Pollard AJ; Cartwright K; Moxon ER
JAMA; 2005 Apr; 293(14):1751-8. PubMed ID: 15827314
[TBL] [Abstract][Full Text] [Related]
47. Immunological effect of administration of sequential doses of Haemophilus influenzae type b and pneumococcal conjugate vaccines in the same versus alternating limbs in the routine infant immunisation schedule: an open-label randomised controlled trial.
Iro MA; Khatami A; Marshall AS; Pace D; Voysey M; McKenna J; Campbell D; Attard-Montalto S; Finn A; White C; Faust SN; Kent A; Heath PT; MacLeod E; Stanford E; Findlow H; Almond R; Bai X; Borrow R; Snape MD; Pollard AJ
Lancet Infect Dis; 2015 Feb; 15(2):172-80. PubMed ID: 25577661
[TBL] [Abstract][Full Text] [Related]
48. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.
McVernon J; Nolan T; Richmond P; Reynolds G; Nissen M; Lambert SB; Marshall H; Papa T; Rehm C
Pediatr Infect Dis J; 2012 Jan; 31(1):e15-23. PubMed ID: 22094636
[TBL] [Abstract][Full Text] [Related]
49. Long-term antibody persistence after a booster dose of quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in healthy 5-year-old children.
Vesikari T; Forsten A; Laudat F; Li P; Van Der Wielen M; Hezareh M; Perez JL; Webber C
Vaccine; 2020 May; 38(22):3902-3908. PubMed ID: 32284274
[TBL] [Abstract][Full Text] [Related]
50. Safety and immunogenicity of a diphtheria, tetanus, acellular pertussis and Haemophilus influenzae Type b combination vaccine compared with separate administration of licensed equivalent vaccines in Chinese infants and toddlers for primary and booster immunization.
Li G; Zhang H; Zhou W; Ye Q; Li F; Wang H; Hou Q; Xu Y; Ma X; Tan Y; Wang L; Li Y; Li H; Meng F; Liang Q; Liu A; Qin C; Wei W; Liu J; Ruan C; Tao W; Zhang S; Zheng H; Zhu F
Vaccine; 2010 Jun; 28(25):4215-23. PubMed ID: 20399240
[TBL] [Abstract][Full Text] [Related]
51. A randomized study to evaluate the immunogenicity and safety of a heptavalent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, haemophilus influenzae b, and meningococcal serogroup C combination vaccine administered to infants at 2, 4 and 12 months of age.
Thollot F; Scheifele D; Pankow-Culot H; Cheuvart B; Leyssen M; Ulianov L; Miller JM
Pediatr Infect Dis J; 2014 Dec; 33(12):1246-54. PubMed ID: 25037033
[TBL] [Abstract][Full Text] [Related]
52. Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine.
Borrow R; Andrews N; Findlow H; Waight P; Southern J; Crowley-Luke A; Stapley L; England A; Findlow J; Miller E
Clin Vaccine Immunol; 2010 Jan; 17(1):154-9. PubMed ID: 19906895
[TBL] [Abstract][Full Text] [Related]
53. A comparative study to evaluate the safety and immunogenicity of two lots of Haemophilus influenzae type-B conjugate vaccine manufactured at different scales.
Hirve S; Bavdekar A; Juvekar S; Agarwal D; Barde P; Mangrule S; Patwardhan M; Pandit A; Kulkarni PS
Vaccine; 2011 Jul; 29(33):5363-7. PubMed ID: 21651947
[TBL] [Abstract][Full Text] [Related]
54. MenHibrix: a new combination meningococcal vaccine for infants and toddlers.
Hale SF; Camaione L; Lomaestro BM
Ann Pharmacother; 2014 Mar; 48(3):404-11. PubMed ID: 24353263
[TBL] [Abstract][Full Text] [Related]
55. Evaluation of De-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic priming, and bactericidal activity against O-acetylated and De-O-acetylated serogroup C strains.
Richmond P; Borrow R; Findlow J; Martin S; Thornton C; Cartwright K; Miller E
Infect Immun; 2001 Apr; 69(4):2378-82. PubMed ID: 11254596
[TBL] [Abstract][Full Text] [Related]
56. Dose response of CRM197 and tetanus toxoid-conjugated Haemophilus influenzae type b vaccines.
Huebner RE; Nicol M; Mothupi R; Käyhty H; Mbelle N; Khomo E; Klugman KP
Vaccine; 2004 Dec; 23(6):802-6. PubMed ID: 15542205
[TBL] [Abstract][Full Text] [Related]
57. Persistence of immunity following a booster dose of Haemophilus influenzae type B-Meningococcal serogroup C glycoconjugate vaccine: follow-up of a randomized controlled trial.
Khatami A; Snape MD; John T; Westcar S; Klinger C; Rollinson L; Boutriau D; Mesaros N; Wysocki J; Galaj A; Yu LM; Pollard AJ
Pediatr Infect Dis J; 2011 Mar; 30(3):197-202. PubMed ID: 20844459
[TBL] [Abstract][Full Text] [Related]
58. Quadrivalent meningococcal (MenACWY-TT) conjugate vaccine or a fourth dose of H. influenzae-N. meningitidis C/Y conjugate vaccine (HibMenCY-TT) is immunogenic in toddlers who previously received three doses of HibMenCY-TT in infancy.
Leonardi M; Latiolais T; Sarpong K; Simon M; Twiggs J; Lei P; Rinderknecht S; Blatter M; Bianco V; Baine Y; Friedland LR; Miller JM
Vaccine; 2015 Feb; 33(7):933-41. PubMed ID: 25152325
[TBL] [Abstract][Full Text] [Related]
59. Antibody persistence up to 5 years after vaccination of toddlers and children between 12 months and 10 years of age with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine.
Vesikari T; Forsten A; Bianco V; Van der Wielen M; Miller JM
Hum Vaccin Immunother; 2016; 12(1):132-9. PubMed ID: 26575983
[TBL] [Abstract][Full Text] [Related]
60. Concomitant administration of a fully liquid ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal ACWY conjugate vaccine in toddlers.
Vesikari T; Borrow R; Da Costa X; Thomas S; Eymin C; Boisnard F; Lockhart S
Vaccine; 2018 Dec; 36(52):8019-8027. PubMed ID: 30471953
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
